Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies announced positive 30-day clinical and hemodynamic outcomes for its Medium-size DurAVR Transcatheter Heart Valve in 22 severe aortic stenosis patients. The valve demonstrated single-digit mean gradients, large effective orifice areas, no moderate or severe paravalvular leaks, and zero valve-related mortality. The company is advancing its PARADIGM pivotal trial, a randomized controlled study comparing DurAVR to commercially available TAVR devices in approximately 1,000 patients.